Immunotherapy for Merkel cell carcinoma — novel research highlights quality of life benefitsEurekAlert (press release)Future Science Group (FSG) today announced the publication of an article in Future Oncology that has demonstrated in patients with me… Continue reading
BSA bureau (press release)CRISPR has success in treating mice with type 1 diabetesDiabetes.co.ukAmerican scientists adapted the gene editing technology known as CRISPR (clustered, regularly interspaced, short palindromic repeat) to successfully treat m… Continue reading
Synthetic Biology Market Growth Analysis to 2022 – NewsientNewsient (blog)HTF MI published a new industry research that focuses on Synthetic Biology market and delivers in-depth market analysis and future prospects of Global Synthetic Biology market. … Continue reading
BioScholar NewsNew CRISPR technique reverses diabetes and kidney failure in mice without cutting DNABioNewsScientists in California have used a modified form of the CRISPR/Cas9 genome editing approach to epigenetically treat diabetes, kidney disease an… Continue reading
|
Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust …
Digital Journal CAMBRIDGE, Mass.–(Business Wire)–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 … |
|
Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust …
Business Wire (press release) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 … |
|
Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust …
Business Wire (press release) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 … |
|
Immunotherapy Combo Effective Against Rare Non-Hodgkin Lymphoma
Specialty Pharmacy Times AbbVie recently announced positive results from a phase 3 clinical trial investigating ibrutinib (Imbruvica) plus rituximab in patients with Waldenström’s macroglobulinemia (WM), a rare non-Hodgkin lymphoma. Only 1000 to 1500 patients are diagnosed … |